Vor Bio announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first- in-human study of tremtelectogene empogeditemcel or "trem-cel" (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. The clinical trial continues to enroll patients and additional data are expected in 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.01 USD | 0.00% |
|
+6.99% | -55.11% |
Jul. 01 | Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000E Value Index | CI |
Jul. 01 | Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2000 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.11% | 68.94M | |
+21.79% | 47.96B | |
+0.76% | 42.45B | |
+43.96% | 41.47B | |
+26.43% | 31.6B | |
+20.90% | 28.63B | |
-4.47% | 28.03B | |
+52.01% | 14.56B | |
+45.20% | 14.14B | |
+2.84% | 12.58B |
- Stock Market
- Equities
- VOR Stock
- News Vor Biopharma Inc.
- Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel and Tolerated Mylotarg(Tm)